Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients

Toujinkai Hospital

Status: Completed

Conditions: Acute Myocardial Infarction; Congestive Heart Failure

Treatments: Drug: Nicorandil

Study type: Interventional

Funder types: Other

Identifiers

NCT00848562

NICO-HDPCI-1

Details and patient eligibility

About

Survival after invasive coronary revascularization is worse in patients with chronic kidney disease than in those without it. The investigators aimed to examine whether oral administration of nicorandil, a hybrid of nitrate and adenosine triphosphate-sensitive potassium channel opener, could improve the survival of end-stage renal disease patients with coronary artery disease by inhibiting cardiac death after coronary revascularization.

Enrollment: 129 patients

Sex: All

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hemodialysis patients with coronary artery disease who had undergone a successful first PCI with bare-metal stents between July 1, 2001 and December 31, 2003.

Exclusion criteria

• Subjects with moderate or worse cardiac valvular disease or old myocardial infarction at the point of first PCI.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

129 participants in 1 patient group

Nicorandil

Experimental group

Treatment:

Drug: Nicorandil